DART and laboratory monitoring of HIV treatment

The Lancet

Volumn 375, Issue 9719, 2010, Pages 979-

  Sayana, Shilpa ^a   Manchanda, Rishi ^a   Khanlou, Homayoon ^a   Saavedra, Jorge ^a   Reis, Peter ^a   Weinstein, Michael ^a  

^a AIDS HEALTHCARE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CLINICAL EVALUATION; CLINICAL TRIAL; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SURVIVAL; AFRICA; DRUG MONITORING; NOTE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AFRICA; ANTI-RETROVIRAL AGENTS; DRUG MONITORING; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 77949477628     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60430-8     Document Type: Letter

References (4)

1. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 (2010) 123-131
2. Phillips A., and Oosterhout J.V. DART points the way for HIV treatment programmes. Lancet 375 (2010) 96-98
3. Sayana S., Manchanda R., Khanlou H., et al. DART: avoid a different standard of care?. J AIDS 53 (2010) 153-154
4. Taverne B, Laniece I, Desclaux A, Vinard P. Free antiretroviral medication for patients in Africa: the indispensable precondition for universal access. International Conference on AIDS; Bangkok, Thailand; July 11-16, 2004; abstr TuPeE5414.